Editor-in-Chief Emeritus |
---|
| Seung Up Kim (2020-2023) | Yonsei University, Korea |
|
Seung Up Kim is a Professor of Internal Medicine at Yonsei University College of Medicine and the Chief of the Fatty Liver Clinic at Severance Hospital in Seoul, Korea. Professor Kim has developed active intellectual collaborations and close personal connections with hepatologists across Asia, the United States, and Europe. He has authored more than 350 peer-reviewed papers in the field of hepatology. His major research interests include viral hepatitis, non-invasive assessment of liver fibrosis and steatosis, anti-fibrotic treatment, and liver cancer. Between 2020 and 2023, as the Editor-in-Chief of CMH, Professor Kim sought to focus on three key values to create a solid platform for effective and up-to-date scientific communication: 1) a rapid publication process, 2) fairness with clear conflict of interest policies, and 3) transparency. In 2020, CMH received an impact factor of 3.8. However, by 2023, its impact factor increased to 8.9, making CMH one of the top international journals in the field of hepatology. Moreover, in 2023, Professor Kim has served as a member of the editorial boards of Clinical Gastroenterology and Hepatology and Journal of Gastroenterology and Hepatology, as an Associate Editor of Gut and Liver, as well as an Academic Editor of PLOS One, Journal of Clinical and Translational Hepatology, and International Journal of Molecular Science. |
|
| Yoon Jun Kim (2016-2019) | Seoul National University, Korea |
|
Dr. Yoon Jun Kim MD, PhD has been Professor of Medicine at Seoul National University College of Medicine since 2013. While doing so, he remains active in the medical community through taking on leading roles in various professional societies such as Chair of the Academic Committee of The Korean Radio-Embolization Association, a position he has held since 2013, and from 2013 to 2014, he functioned as Chair of Academic Committee of The Korean Liver Cancer Study Group. Also, he served as secretary general of The Korean Liver Cancer Study Group from 2014 to 2015 and as Editor-in-Chief of Clinical and Molecular Hepatology from 2016 to 2019. Currently, he is the president of The Korean Radio-Embolization Association and was appointed as the successor president of The Korean NAFLD Study Group. His educational background began in the same college that he is now professor at, where he graduated from Seoul National University College of Medicine in 1992 and later went on to attain his Ph.D. there in 2001. His research interests in his particular field have included clinical studies of HBV infection and HCC, drug development for functional cure of HBV infection, host genomics in HBV-related liver disease, drug development and clinical studies of NASH, cancer genomics of HCC, and basic studies of HCC pathogenesis. |
|